BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29130344)

  • 1. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
    Rapoport BL; Jordan K; Weinstein C
    Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
    Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Vallejos W; Liang LW; Noga SJ; Rapoport BL
    Ann Oncol; 2016 Jan; 27(1):172-8. PubMed ID: 26449391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
    Navari RM
    Future Oncol; 2019 Jan; 15(3):241-255. PubMed ID: 30304952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
    Navari RM
    Expert Opin Drug Saf; 2019 Dec; 18(12):1127-1132. PubMed ID: 31622113
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
    Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
    Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
    Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
    BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.
    Mora J; Valero M; DiCristina C; Jin M; Chain A; Bickham K
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27690. PubMed ID: 30900392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):e200-e201. PubMed ID: 30653479
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
    Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
    Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
    BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis.
    Zhang Y; Hou X; Zhang R; Chen G; Huang Y; Yang Y; Zhao Y; Fang W; Hong S; Kang S; Zhou T; Zhang Z; Chen X; Zhang L
    Future Oncol; 2018 Aug; 14(19):1933-1941. PubMed ID: 30019968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
    Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
    J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
    Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
    Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
    Garnock-Jones KP
    Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
    Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
    Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
    Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
    Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review.
    Xue F; Liu X; Qi X; Zhou J; Liu Y
    Adv Clin Exp Med; 2023 Jun; 32(6):701-706. PubMed ID: 37026971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
    Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic evaluation of fosaprepitant dimeglumine.
    Colon-Gonzalez F; Kraft WK
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1277-86. PubMed ID: 20795794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.